246 related articles for article (PubMed ID: 30596701)
1. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
2. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
3. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
4. HCV disease burden and population segments in Switzerland.
Bihl F; Bruggmann P; Castro Batänjer E; Dufour JF; Lavanchy D; Müllhaupt B; Negro F; Razavi H; Scheidegger C; Semela D; Semmo N; Blach S
Liver Int; 2022 Feb; 42(2):330-339. PubMed ID: 34839578
[TBL] [Abstract][Full Text] [Related]
5. The current and future burden of hepatitis B in Switzerland: a modelling study.
Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
[TBL] [Abstract][Full Text] [Related]
6. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
7. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
10. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
11. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
12. Global burden of hepatitis C: considerations for healthcare providers in the United States.
Averhoff FM; Glass N; Holtzman D
Clin Infect Dis; 2012 Jul; 55 Suppl 1():S10-5. PubMed ID: 22715208
[TBL] [Abstract][Full Text] [Related]
13. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Semela D; Negro F
PLoS One; 2015; 10(6):e0125214. PubMed ID: 26107467
[TBL] [Abstract][Full Text] [Related]
14. Simulation of hepatitis C based on a mandatory reporting system.
Sagmeister M; Renner EL; Mullhaupt B; Wong JB
Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):25-34. PubMed ID: 11782572
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
16. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
[TBL] [Abstract][Full Text] [Related]
17. Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.
McDonald SA; Dahlui M; Mohamed R; Naning H; Shabaruddin FH; Kamarulzaman A
PLoS One; 2015; 10(6):e0128091. PubMed ID: 26042425
[TBL] [Abstract][Full Text] [Related]
18. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
19. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
20. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
